Skip Navigation
  Print Page

Male Contraceptive Development Program (MCDP)

Skip sharing on social media links
Share this:


Consultation of doctor and male patient The MCDP is a cooperative research program formed in an effort to expand research leading to the development of male contraception. The Contraceptive Discovery and Development Branch (CDDB), formerly the Contraception and Reproductive Health (CRH) Branch , in collaboration with the other NICHD Branches, initiated and restructured programs, including the MCDP, to encourage a spectrum of activities leading to development of novel male contraceptives.

The Program is funded through a Cooperative Agreement Research award mechanism (U01) and a Specialized Cooperative Research Center award mechanism (U54). The Program includes sites that are also participating in other CDDB Branch research programs, such as the Contraceptive Development Research Center Program (nine projects in three centers) and the Contraceptive Clinical Trials Network (CCTN). The Program also relies on existing contracts for Chemical Synthesis, Peptide Synthesis, and Medicinal Chemistry facilities to develop and synthesize new drugs and to produce bulk quantities of drugs, under current Good Manufacturing Practices, for use in clinical trials.

Topic Areas

Research in the MCDP includes basic, translational, and clinical studies on topics such as mechanisms that regulate sperm maturation and identification of new therapeutic targets for male contraception.

Other research topics include (but are not limited to):

  • Studies of how mechanisms that regulate sperm maturation (spermiogenesis) might be targeted by novel male contraceptives
  • Studies of the significance of signaling pathways for the protein receptor c-Ros in male fertility
  • Studies of sperm glycolytic enzymes, which are required for sperm motility, as novel contraceptive targets
  • Studies of nonhormonal targets for male contraception, including the tight junctions between Sertoli cells and germ cells, which are required for appropriate cell-cell interactions during sperm development (spermatogenesis)
  • Clinical trials in men using an injectable formulation of Acyline, a potent gonadotropin-releasing hormone antagonist, to assess drug safety and ability to suppress spermatogenesis
  • Development and characterization of novel male contraceptives, including H2-gamendazole, an orally active anti-spermatogenic compound
  • Studies of pharmaceutical targeting of a sperm-specific calcium cation channel (CatSper) and consequences of targeting on male fertility
  • Selective inhibition of BRDT for male contraception

Current Sites

  • Baylor College of Medicine (Houston, TX)
  • Children’s Hospital Boston, Harvard University
  • Columbia University (New York, NY)
  •  Harvard Medical School (Boston, MA)
  • Jackson Laboratory (Bar Harbor, ME)
  • Oregon Health and Science University
  • Population Council (New York, NY)
  • University of Florida
  • University of Kansas Medical Center
  • University of Minnesota, Twin Cities
  • University of North Carolina, Chapel Hill
  • University of North Carolina, Charlotte
  • University of Virginia
  • University of Washington
  • Washington State University

More Information

Last Updated Date: 01/24/2014
Last Reviewed Date: 01/24/2014
Vision National Institutes of Health Home BOND National Institues of Health Home Home Storz Lab: Section on Environmental Gene Regulation Home Machner Lab: Unit on Microbial Pathogenesis Home Division of Intramural Population Health Research Home Bonifacino Lab: Section on Intracellular Protein Trafficking Home Lilly Lab: Section on Gamete Development Home Lippincott-Schwartz Lab: Section on Organelle Biology